List of Excipients in Branded Drug VARUBI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	CELLULOSE, MICROCRYSTALLINE	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	CROSCARMELLOSE SODIUM	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	FD&C BLUE NO. 2	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	LACTOSE MONOHYDRATE	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	MAGNESIUM STEARATE	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	POLYETHYLENE GLYCOL	2029-10-09
GlaxoSmithLine LLC	VARUBI	rolapitant	69656-101	POLYSORBATE 80	2029-10-09

Varubi Excipient Strategy and Commercial Opportunities for Rolapitant

Last updated: August 2, 2026

Varubi is the brand name for rolapitant hydrochloride, an NK1 receptor antagonist approved by the FDA for prevention of delayed chemotherapy-induced nausea and vomiting. The commercial opportunity is concentrated in oral solid-dose reformulation, generic tablet supply, excipient differentiation, and selected hospital-use presentations. The injectable formulation has limited commercial attractiveness because of safety-related market withdrawal and higher formulation complexity.

What is Varubi and how is it administered?

Varubi was developed by Tesaro, later acquired by GSK. The oral product contains 180 mg of rolapitant hydrochloride and is administered with a 5-HT3 receptor antagonist and dexamethasone in patients receiving moderately or highly emetogenic chemotherapy.

Product	Active ingredient	Strength	Dosage form	FDA status
Varubi tablets	Rolapitant hydrochloride	180 mg	Film-coated tablet	Approved
Varubi injection	Rolapitant hydrochloride	166.5 mg/92.5 mL	Intravenous emulsion	Approved, later withdrawn from U.S. marketing

The oral dose is generally given approximately two hours before chemotherapy, with no more than one dose in a 14-day period. Rolapitant has a long terminal half-life, approximately seven days, which supports delayed-phase antiemetic coverage but also increases the importance of drug-drug interaction management.[1]

The injectable product was withdrawn after reports of anaphylaxis and other hypersensitivity reactions associated with the intravenous formulation. The withdrawal materially reduces the value of injectable-excipient opportunities compared with oral products.[2]

What excipients are used in Varubi tablets?

The Varubi tablet is a conventional immediate-release, film-coated tablet. The listed inactive ingredients include standard solid-dose excipients used for direct compression or wet granulation systems.

Varubi tablet excipient profile

Functional role	Excipient category used in the product
Diluent	Lactose monohydrate
Filler and compression aid	Microcrystalline cellulose
Disintegrant	Croscarmellose sodium
Binder	Povidone
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate
Film coating	Polyvinyl alcohol-based coating system with pigments and opacifiers

The formulation is commercially conventional. It does not depend on a complex controlled-release matrix, lipid system, amorphous solid dispersion, enteric coating, or device-based delivery platform. That structure lowers manufacturing barriers for a generic manufacturer but creates room for differentiated products based on patient acceptability, excipient exclusion, and manufacturing efficiency.

The exact commercial formulation should be assessed against the current FDA-approved labeling and any post-approval manufacturing changes. FDA labeling identifies inactive ingredients but does not, by itself, establish whether any specific excipient combination is patent-protected.[1]

How does rolapitant’s drug substance affect excipient selection?

Rolapitant is a lipophilic, relatively high-molecular-weight small molecule with limited aqueous solubility. The commercial tablet uses a conventional solid-dose platform rather than a high-energy solubilization system. Excipient selection therefore needs to address four practical requirements:

1. Adequate powder flow and content uniformity.
2. Rapid tablet disintegration.
3. Reproducible dissolution across manufacturing sites.
4. Physical and chemical stability during long-term storage.

Lactose and microcrystalline cellulose provide bulk and compression performance. Croscarmellose sodium supports rapid breakup of the tablet. Povidone improves granule or compact strength, while colloidal silicon dioxide and magnesium stearate control processing behavior.

The main technical risk is not dose size. A 180 mg active dose is manageable for a conventional tablet. The greater risk is dissolution variability caused by drug-substance particle size, polymorphic form, crystal habit, lubricant level, and granulation conditions. Excessive magnesium stearate or over-lubrication can reduce wetting and slow dissolution. Excessive compression force can produce a tablet that passes hardness testing but disintegrates slowly.

What excipient strategies could improve Varubi products?

Lactose-free formulation

A lactose-free rolapitant tablet is the clearest patient-focused opportunity. Lactose monohydrate is used in the reference product, creating a potential market for a formulation based on mannitol, silicified microcrystalline cellulose, anhydrous dibasic calcium phosphate, or a low-moisture polyol system.

The commercial case is strongest where hospitals or oncology clinics use excipient-exclusion protocols. A lactose-free product could also simplify procurement for patients with lactose intolerance, although lactose intolerance is not equivalent to a clinically significant allergy.

The primary technical tradeoff is manufacturability. Mannitol can improve mouthfeel and reduce hygroscopicity but may require a different binder and compression strategy. Calcium phosphate improves tablet strength but can affect dissolution and may be less suitable for a formulation seeking a rapid-release profile.

Low-moisture formulation

A low-moisture tablet may improve stability if rolapitant or the selected salt form is sensitive to hydrolysis. An anhydrous lactose or calcium phosphate platform could reduce water activity compared with lactose monohydrate. The manufacturer would need to balance this benefit against dissolution performance, especially under biorelevant conditions.

Direct-compression platform

A direct-compression formulation can reduce unit operations, shorten manufacturing time, and improve scale-up economics. A likely platform would use:

• Microcrystalline cellulose or silicified microcrystalline cellulose for compactibility.
• A superdisintegrant such as croscarmellose sodium or crospovidone.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or a lower-impact lubricant.

This strategy is commercially attractive for generic manufacturers because it reduces granulation equipment requirements. It also creates a process-development opportunity for excipient suppliers that can demonstrate consistent flow, low lubricant sensitivity, and robust dissolution.

Orally disintegrating tablet

An orally disintegrating tablet could address patients experiencing nausea, swallowing difficulty, or chemotherapy-related mucositis. The product would need to deliver 180 mg of active ingredient, which is a relatively large payload for an ODT. A compressed ODT could be feasible, but a highly palatable formulation would be difficult because the drug substance may contribute bitterness or an unpleasant mouthfeel.

An ODT would likely require taste masking, a porous compact, and a high-performance disintegrant. Mannitol, crospovidone, flavoring, and a polymeric taste-masking system could be considered. The regulatory value would depend on whether the product delivers a clinically meaningful administration advantage rather than merely changing tablet format.

Oral powder or sprinkle formulation

A powder or sprinkle product could target patients who cannot swallow tablets. This route is less attractive than an ODT because dose uniformity, taste masking, packaging, and handling become more demanding. A single-dose sachet may be commercially viable in pediatric or supportive-care settings, but the target population for rolapitant is primarily oncology patients receiving chemotherapy, and pediatric use is not the central approved indication.

Liquid oral formulation

An oral suspension or solution would require substantial development work because of rolapitant’s limited solubility and the need for physical stability. A suspension could use wetting agents, suspending polymers, preservatives, and taste-masking excipients. A solution could require cosolvents or surfactants that increase tolerability and regulatory scrutiny.

A liquid product would have the strongest value in patients with dysphagia, but its development cost and stability burden would exceed that of a tablet. It could support a 505(b)(2) strategy if the formulation offers a clinically relevant administration benefit and relies partly on the established rolapitant safety and efficacy record.[3]

What formulation patents protect Varubi?

The commercial Varubi tablet is based on an established immediate-release formulation. Public FDA labeling identifies excipients but does not provide a complete freedom-to-operate analysis for formulation patents, manufacturing patents, or patent families in every jurisdiction.

Patent risk should be divided into four categories:

Patent category	Relevance to rolapitant
Compound patents	May cover rolapitant and related chemical structures
Salt and crystal-form patents	May cover rolapitant hydrochloride, polymorphs, or crystalline forms
Formulation patents	Could cover excipient combinations, dissolution performance, or solid-state stabilization
Method-of-use patents	Could cover chemotherapy regimens, delayed nausea prevention, or combination therapy

A generic applicant would typically evaluate listed patents in the FDA Orange Book, relevant unlisted patents, regulatory exclusivity, and patent litigation history before filing an ANDA.[4] Excipient substitution does not eliminate infringement risk if a patent claims the active ingredient, salt form, polymorph, dosage regimen, or broad formulation characteristics.

The strongest design-around opportunity generally comes from a non-infringing formulation that uses a different excipient architecture while achieving equivalent dissolution and bioequivalence. A formulation patent would need to claim more than the mere presence of standard excipients to create a durable barrier.

When does Varubi lose exclusivity and what generic entry risks exist?

Regulatory exclusivity and patent exclusivity must be analyzed separately. FDA approval of the oral product occurred in 2015. The U.S. reference product may have received five-year new chemical entity exclusivity, with possible additional exclusivity associated with pediatric studies or other regulatory actions. Patent expiration depends on the specific patent family, patent-term adjustment, terminal disclaimers, and any patent-term extension.

The commercial generic-entry pathway is an ANDA for an equivalent 180 mg tablet. A first applicant may file a Paragraph IV certification against an Orange Book-listed patent and potentially obtain 180 days of exclusivity if statutory conditions are met. Later applicants may use Paragraph III certifications or wait for the relevant patents to expire.[4]

Generic launch scenarios

Scenario	Commercial effect
No active blocking patent	Multiple ANDA applicants could enter, causing rapid price erosion
One Paragraph IV challenger	Litigation may delay launch but can create an early-entry settlement
Authorized generic	Brand or licensee supply can reduce first-generic economics
Formulation differentiation	May preserve a premium niche but will not prevent standard generic entry
Limited chemotherapy volume	Smaller market may support fewer entrants than a primary-care product

Rolapitant has a narrower market than broad-use antiemetics such as ondansetron. That reduces absolute revenue potential but may also reduce the number of generic manufacturers willing to invest in a technically complex submission.

What is the Orange Book and FDA status of Varubi?

The FDA Orange Book is the primary U.S. source for approved drug products, therapeutic-equivalence evaluations, and listed patents or exclusivity information. Varubi’s regulatory analysis should distinguish the oral tablet from the injectable emulsion because the products have different dosage forms, manufacturing risks, and commercial histories.[4]

The oral product has the more relevant pathway for current commercial analysis. The injectable product has limited value as a follow-on target because of the hypersensitivity history and the added burden of emulsion development, container compatibility, sterilization, and clinical risk management.

FDA approval does not guarantee current commercial availability. Brand discontinuation, supply interruption, or removal from active commercial distribution can create a separate opportunity for an ANDA holder, contract manufacturer, or licensee. FDA’s drug databases and official labeling should be used to confirm current marketing status.[1,5]

How strong is the Varubi patent estate?

The patent estate is commercially meaningful only if it includes unexpired claims that block the active ingredient, a required salt or polymorph, a clinically important use, or a formulation that cannot be readily designed around.

From an excipient perspective, the likely strength profile is moderate rather than high:

• The tablet uses common excipients.
• The product is immediate release.
• The active dose is suitable for conventional tableting.
• Multiple substitute excipient systems are technically plausible.
• A generic manufacturer can potentially preserve bioequivalence through particle-size control and dissolution optimization.

Patent strength would be higher if the relevant claims cover a specific rolapitant crystal form, a narrow dissolution profile tied to in vivo performance, or a formulation that solves a demonstrated stability problem. Generic risk would be lower if those claims are valid, unexpired, and difficult to design around.

Which companies are positioned to challenge Varubi?

The most likely challengers are established generic manufacturers with oncology portfolios and experience in ANDA litigation or Paragraph IV filings. The product’s relatively narrow market may favor companies that already manufacture antiemetics, oncology supportive-care products, or hospital-administered medicines.

Potential commercial participants include:

• Large multinational generic manufacturers.
• Specialty oncology-generic companies.
• Contract development and manufacturing organizations with tablet and coating capacity.
• Excipient suppliers seeking preferred-supplier status through a differentiated formulation.
• Licensees acquiring rights to an approved or near-approved rolapitant product.

A biosimilar strategy is not relevant because rolapitant is a chemically synthesized small molecule. The competitive framework is generic substitution, not the biologics reference-product pathway.

What licensing and commercial opportunities exist?

The most credible opportunities are:

Generic tablet licensing

A company with an approved or bioequivalent tablet could license regional rights to a generic manufacturer with oncology sales infrastructure. The relatively narrow indication makes distribution reach and hospital contracting more important than consumer marketing.

Excipient-enabled reformulation

An excipient supplier could support a lactose-free, low-moisture, direct-compression, or ODT program. The supplier’s value would come from formulation data, process robustness, and regulatory documentation rather than from commodity excipient sales alone.

Regional supply agreements

Rolapitant may have greater value in markets where delayed CINV treatment is reimbursed and where oral antiemetic competition is less concentrated. Regional licensing would require separate review of national patent rights, marketing authorizations, reimbursement, and local excipient requirements.

Hospital and oncology-clinic packaging

Unit-dose blister packaging, calendar packs, and low-volume specialty distribution could improve medication handling. Packaging is not an excipient strategy, but it can support a differentiated commercial proposition for an oncology product administered around chemotherapy cycles.

What patent litigation and settlement issues affect Varubi?

Paragraph IV litigation can delay generic entry even when a generic formulation uses different excipients. The relevant disputes may concern compound claims, salt forms, polymorphs, method-of-use claims, or listed formulation patents.

Settlement agreements may include:

• A fixed generic launch date.
• An authorized-generic arrangement.
• A license limited by geography or dosage form.
• Supply or manufacturing obligations.
• Restrictions on formulation or indication.

A settlement that permits early entry can substantially reduce the value of a standalone formulation patent. Conversely, a strong formulation patent combined with a broad compound patent can support a longer exclusivity period.

No commercial decision should rely on the inactive-ingredient list alone. The Orange Book, FDA approval records, USP requirements, patent prosecution history, court dockets, and settlement terms must be read together.[4,6]

Key Takeaways

• Varubi is rolapitant hydrochloride, an oral NK1 antagonist for delayed chemotherapy-induced nausea and vomiting.
• The commercial tablet uses a conventional immediate-release excipient platform based on lactose, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and film-coating materials.
• The strongest formulation opportunities are lactose-free tablets, low-moisture tablets, direct-compression products, and selected ODT designs.
• The injectable formulation has lower attractiveness because of hypersensitivity concerns and emulsion-development complexity.
• Rolapitant is a small molecule, so biosimilar competition is not relevant.
• Generic entry is likely to depend on Orange Book patents, Paragraph IV certifications, patent-term calculations, and market size.
• Common excipients provide limited inherent patent protection. Durable barriers would more likely arise from compound, salt, polymorph, method-of-use, or narrowly drafted formulation claims.
• Licensing value depends on regional reimbursement, oncology-channel access, formulation differentiation, and the number of economically viable generic entrants.

FAQs

Can a lactose-free rolapitant tablet be approved as a generic?

Yes. A lactose-free formulation could be submitted through an ANDA if it meets the applicable sameness, bioequivalence, quality, and labeling requirements. It may also be considered under a 505(b)(2) pathway if the product introduces a clinically meaningful dosage-form or administration change.

Is Varubi an appropriate candidate for an orally disintegrating tablet?

It is technically possible but commercially challenging. The 180 mg dose creates a high tablet-mass requirement, and taste masking may be necessary. The product would need to demonstrate a meaningful administration benefit for oncology patients.

Does changing excipients avoid Varubi patent infringement?

No. Excipients are only one part of the analysis. A product may still infringe claims covering rolapitant, its salt, a crystal form, a method of use, or broad formulation limitations.

Is a rolapitant injectable emulsion commercially attractive?

The opportunity is limited. The injectable product requires sterile emulsion manufacturing and carries a history of hypersensitivity concerns. Oral solid-dose development has a lower technical and regulatory burden.

What is the most defensible excipient opportunity for rolapitant?

A lactose-free, low-moisture immediate-release tablet with robust dissolution and direct-compression manufacturability is the most practical opportunity. It addresses a defined excipient concern without imposing the development burden of a liquid or injectable product.

References

1. U.S. Food and Drug Administration. (2018). Varubi (rolapitant hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (2020). Varubi injection: safety communications and product status information.
3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
6. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity and ANDA patent certifications.